Week in Review: R&D Fueled By Collaboration

02.28.14 | By

We revisit the research and development (R&D) pipeline quite a bit, because it is a crucially important aspect of modern medicine. Having recently released our Medicines in Development report on the 180 medicines in the pipeline to treat diabetes and related conditions, it is important to recognize the steps that fuel innovation and medical advances.

‘Medicines in Development’ just part of equation to treat diabetes

02.27.14 | By

By 2020, nearly half of all Americans will have at least one chronic condition. As more and more people are afflicted by chronic disease, it is increasingly important to develop new ways to prevent, manage, and treat these life-altering conditions.

Collaborating for Future Progress

02.26.14 | By

The existing model of bringing new medicines to patients is a costly, exhaustive, and thorough process. In fact, to develop a new medicine under the federal process takes about $1 billion and 10 years — with a failure rate of roughly 99 percent.

Intellectual Property Rights Are Crucial to Protect Global Patient Health

02.24.14 | By

Today, I had the opportunity to offer PhRMA’s perspective on inadequate intellectual property (IP) rights and other major trade barriers around the world during the U.S. Trade Representative’s (USTR) public hearing in the 2014 Special 301 Review process.

Peter Huber Explains How 20th Century Law is Undermining 21st Century Medicine

02.20.14 | By

A new book, the Cure in the Code: How 20th Century Law is Undermining 21st Century Medicine, provides a fascinating overview of advances in biomedical science with the potential to revolutionize how diseases are treated by providing patients with more targeted therapies.

PhRMA Statement on Proposed Rule on Medicare Advantage & Part D

Washington, D.C. (February 19, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement:

“PhRMA opposes the proposed rule on Medicare Advantage and Part D that CMS released in early January because it could disrupt care for millions of beneficiaries. The Part D program is already working well, making the proposed rule unnecessary and harmful. Quite simply, it is a solution in search of a problem.

ITC Investigates India Trade Practices

02.17.14 | By

At the International Trade Commission (ITC) hearing on the investigation into India's trade policies, Rod Hunter, PhRMA’s Senior Vice President for International Affairs, highlighted the industry's concerns and hopes surrounding India’s policies.

ITC Testimony

NORD on the Need for More Collaboration to Drive Progress for Rare Disease Patients

02.17.14 | By

Many biopharmaceutical companies are actively engaged in the research and development of therapies to treat rare disease, despite challenges such as much smaller patient populations than more common diseases. Companies seek opportunities to partner with patient advocacy organizations, academia and the government in order to make even greater progress against rare disease, which collectively affect 1 in 10 Americans.

Patient-Centered Pathways for Advancing Cancer Care

02.14.14 | By

There's been a lot of discussion lately about the need to control rising health care costs, and the role of new medicines and medical technology. Nowhere has this discussion been sharper than in the area of oncology. At PhRMA, we’ve been joining in many of these discussions, working with other stakeholders to identify solutions to sustain continued progress and support efficient delivery of optimal patient care.


Subscribe to RSS - Opinion